Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
IR_propancbiopharma
IR_propancbiopharma Sep. 11 at 6:09 PM
$PPCB is targeting February 2027 to begin PRP’s world-first Phase 1b First-In-Human study. Up to 50 patients across pancreatic, ovarian, and refractory prostate cancers will move PRP from preclinical development into human clinical evaluation. A defined clinical milestone—with execution already underway.
1 · Reply
URANIUM77
URANIUM77 Sep. 11 at 2:34 PM
$PPCB Big news is coming
0 · Reply
CapnKrunch
CapnKrunch Sep. 11 at 2:21 PM
$PPCB I may just wait to short this once they cure cancer, because the radio silence from management and no PR will definitely sink this time and time again.
0 · Reply
CapnKrunch
CapnKrunch Sep. 11 at 1:52 PM
$PPCB this company needs some PR to plug this bleeding! This has been an incredibly painful bleed for a couple weeks now. It doesn’t appear there is anyone working in their investor relations department right now 😂. With such a small float, anyone that wants to $100K worth would spike this quick and possibly trigger a squeeze. Standing by…….
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Sep. 10 at 5:21 PM
$PPCB is preparing to take PRP from preclinical development into human clinical evaluation, with its Phase 1b First-In-Human study targeted to begin in February 2027. It’s a milestone that reflects a broader reality in medicine: progress often comes from exploring entirely new ways to treat disease. Across healthcare, innovation is taking many forms—from mRNA-based medicines $MRNA to stem cell-derived approaches being studied in Type 1 diabetes $VRTX. PRP follows a different scientific path, using a proenzyme-based approach designed to target cancer stem cells and mechanisms associated with recurrence and metastasis. Different diseases. Different technologies. The common goal: translating scientific innovation into new possibilities for patients. $PPCB $MRNA $VRTX
0 · Reply
Funktrade
Funktrade Sep. 10 at 5:03 PM
$PPCB COME ON !!! 😡😡losing my patience here
0 · Reply
CrumbEater
CrumbEater Sep. 9 at 10:30 PM
$PPCB stock looks like it's going to .00001
1 · Reply
Funktrade
Funktrade Sep. 9 at 6:17 PM
$PPCB FUCK. ME. 😡😡😡
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Sep. 8 at 8:06 PM
For a development-stage biotech, progress isn't only measured by what happens in the clinic. It's also about protecting science from being built along the way. Propanc's intellectual property strategy is designed to protect PRP and the technologies surrounding its development across multiple potential applications. As PRP advances toward clinical evaluation, that growing IP portfolio becomes an important part of the Company's foundation—supporting differentiation, protecting innovation, and strengthening the long-term value of the underlying technology. Clinical progress builds evidence. IP helps protect what is being built. $PPCB
0 · Reply
URANIUM77
URANIUM77 Sep. 8 at 7:38 PM
$PPCB Load up and Hold for GOLD
0 · Reply
Latest News on PPCB
Propanc Biopharma to commence first-in-human study of PRP in February

2026-09-09T13:05:21.000Z - 5 days ago

Propanc Biopharma to commence first-in-human study of PRP in February

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

Sep 9, 2026, 8:30 AM EDT - 5 days ago

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

Why Is Penny Stock Propanc Biopharma (PPCB) Up 245% Today?

2026-08-27T13:47:38.000Z - 18 days ago

Why Is Penny Stock Propanc Biopharma (PPCB) Up 245% Today?

Propanc Biopharma announces new preclinical data for PRP in PDAC

2026-08-27T12:45:33.000Z - 18 days ago

Propanc Biopharma announces new preclinical data for PRP in PDAC

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

Aug 27, 2026, 8:30 AM EDT - 18 days ago

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

2026-08-18T12:50:18.000Z - 27 days ago

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

Aug 18, 2026, 8:30 AM EDT - 27 days ago

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

Propanc highlights PRP as potential therapy against RAS-driven cancers

2026-08-17T09:24:22.000Z - 4 weeks ago

Propanc highlights PRP as potential therapy against RAS-driven cancers

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma

2026-08-06T13:51:23.000Z - 5 weeks ago

Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Aug 6, 2026, 8:30 AM EDT - 5 weeks ago

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Aug 5, 2026, 8:30 AM EDT - 5 weeks ago

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Jul 21, 2026, 8:30 AM EDT - 7 weeks ago

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Propanc Biopharma registers to sell 2.5M shares of common stock for holders

2026-07-17T21:35:21.000Z - 1 month ago

Propanc Biopharma registers to sell 2.5M shares of common stock for holders

Propanc Biopharma signs MOU with Avance Clinical for PRP clinical trial

2026-07-07T13:06:21.000Z - 2 months ago

Propanc Biopharma signs MOU with Avance Clinical for PRP clinical trial

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

Jul 7, 2026, 8:30 AM EDT - 2 months ago

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

Propanc Biopharma initiates share repurchase program

2026-07-02T12:55:35.000Z - 2 months ago

Propanc Biopharma initiates share repurchase program

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Jul 2, 2026, 8:30 AM EDT - 2 months ago

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Propanc CEO visits European manufacturer ahead of drug production plan

2026-06-16T13:41:11.000Z - 3 months ago

Propanc CEO visits European manufacturer ahead of drug production plan

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Jun 16, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Propanc Biopharma announces $5M share repurchase program

2026-06-11T13:14:59.000Z - 3 months ago

Propanc Biopharma announces $5M share repurchase program

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Jun 11, 2026, 8:30 AM EDT - 3 months ago

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Jun 2, 2026, 5:30 AM EDT - 3 months ago

Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

May 20, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Propanc Biopharma engages European CDMO for GMP production of PRP

2026-05-19T13:16:34.000Z - 3 months ago

Propanc Biopharma engages European CDMO for GMP production of PRP

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

May 19, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

Propanc Biopharma Inc trading halted, news pending

2026-05-15T23:51:01.000Z - 4 months ago

Propanc Biopharma Inc trading halted, news pending

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

May 15, 2026, 8:45 AM EDT - 4 months ago

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

Propanc Biopharma announces 1-for-25 reverse stock split

2026-05-14T09:34:08.000Z - 4 months ago

Propanc Biopharma announces 1-for-25 reverse stock split

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

May 13, 2026, 10:00 PM EDT - 4 months ago

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma files to sell 15M shares of common stock for holders

2026-04-10T21:35:15.000Z - 5 months ago

Propanc Biopharma files to sell 15M shares of common stock for holders

Propanc Biopharma signs multi-year collaboration with Spanish universities

2026-03-24T13:11:19.000Z - 5 months ago

Propanc Biopharma signs multi-year collaboration with Spanish universities

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Mar 24, 2026, 8:45 AM EDT - 5 months ago

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Propanc Biopharma announces highlights of PRP

2026-03-12T13:04:12.000Z - 6 months ago

Propanc Biopharma announces highlights of PRP

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Mar 12, 2026, 8:45 AM EDT - 6 months ago

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Propanc Biopharma executes service agreement with FyoniBio

2026-03-10T12:51:18.000Z - 6 months ago

Propanc Biopharma executes service agreement with FyoniBio

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Mar 10, 2026, 8:45 AM EDT - 6 months ago

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Propanc Biopharma highlights potential of lead asset PRP

2026-03-03T13:59:37.000Z - 6 months ago

Propanc Biopharma highlights potential of lead asset PRP

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Mar 3, 2026, 8:45 AM EST - 6 months ago

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Feb 18, 2026, 8:45 AM EST - 6 months ago

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Feb 5, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Jan 27, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Jan 20, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Jan 15, 2026, 8:45 AM EST - 8 months ago

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma Provides Shareholder Update

Jan 13, 2026, 8:45 AM EST - 8 months ago

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22, 2025, 7:00 AM EST - 8 months ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 4, 2025, 8:45 AM EST - 9 months ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Dec 1, 2025, 8:45 AM EST - 9 months ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 17, 2025, 8:45 AM EST - 10 months ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 10, 2025, 8:45 AM EST - 10 months ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Nov 4, 2025, 7:00 AM EST - 10 months ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 5:45 PM EDT - 11 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 11 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Oct 7, 2025, 8:45 AM EDT - 11 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 17, 2025, 8:45 AM EDT - 12 months ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Sep 2, 2025, 9:00 AM EDT - 1 year ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 1 year ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 1 year ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

IR_propancbiopharma
IR_propancbiopharma Sep. 11 at 6:09 PM
$PPCB is targeting February 2027 to begin PRP’s world-first Phase 1b First-In-Human study. Up to 50 patients across pancreatic, ovarian, and refractory prostate cancers will move PRP from preclinical development into human clinical evaluation. A defined clinical milestone—with execution already underway.
1 · Reply
URANIUM77
URANIUM77 Sep. 11 at 2:34 PM
$PPCB Big news is coming
0 · Reply
CapnKrunch
CapnKrunch Sep. 11 at 2:21 PM
$PPCB I may just wait to short this once they cure cancer, because the radio silence from management and no PR will definitely sink this time and time again.
0 · Reply
CapnKrunch
CapnKrunch Sep. 11 at 1:52 PM
$PPCB this company needs some PR to plug this bleeding! This has been an incredibly painful bleed for a couple weeks now. It doesn’t appear there is anyone working in their investor relations department right now 😂. With such a small float, anyone that wants to $100K worth would spike this quick and possibly trigger a squeeze. Standing by…….
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Sep. 10 at 5:21 PM
$PPCB is preparing to take PRP from preclinical development into human clinical evaluation, with its Phase 1b First-In-Human study targeted to begin in February 2027. It’s a milestone that reflects a broader reality in medicine: progress often comes from exploring entirely new ways to treat disease. Across healthcare, innovation is taking many forms—from mRNA-based medicines $MRNA to stem cell-derived approaches being studied in Type 1 diabetes $VRTX. PRP follows a different scientific path, using a proenzyme-based approach designed to target cancer stem cells and mechanisms associated with recurrence and metastasis. Different diseases. Different technologies. The common goal: translating scientific innovation into new possibilities for patients. $PPCB $MRNA $VRTX
0 · Reply
Funktrade
Funktrade Sep. 10 at 5:03 PM
$PPCB COME ON !!! 😡😡losing my patience here
0 · Reply
CrumbEater
CrumbEater Sep. 9 at 10:30 PM
$PPCB stock looks like it's going to .00001
1 · Reply
Funktrade
Funktrade Sep. 9 at 6:17 PM
$PPCB FUCK. ME. 😡😡😡
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Sep. 8 at 8:06 PM
For a development-stage biotech, progress isn't only measured by what happens in the clinic. It's also about protecting science from being built along the way. Propanc's intellectual property strategy is designed to protect PRP and the technologies surrounding its development across multiple potential applications. As PRP advances toward clinical evaluation, that growing IP portfolio becomes an important part of the Company's foundation—supporting differentiation, protecting innovation, and strengthening the long-term value of the underlying technology. Clinical progress builds evidence. IP helps protect what is being built. $PPCB
0 · Reply
URANIUM77
URANIUM77 Sep. 8 at 7:38 PM
$PPCB Load up and Hold for GOLD
0 · Reply
URANIUM77
URANIUM77 Sep. 8 at 7:37 PM
$PPCB It is coming Load up and Hold strong
0 · Reply
Tillhair
Tillhair Sep. 8 at 1:51 PM
$PPCB good
0 · Reply
Funktrade
Funktrade Sep. 8 at 12:13 AM
$PPCB need $1.50 this week
1 · Reply
strong_Dan
strong_Dan Sep. 5 at 12:59 PM
$PPCB Some 'good news , since some people focus on 'the nice :) : James Nathanielsz, the CEO, despite adding 1M shares on 21 August to his previos 400k, during the history of the stock, adjusted for the splits, he never sold what he received. So the vision might still be there. We don't know what the other directors do out of the recent 2.5M approved shares. The expected seller (cash generator for the company) is Hexstone , when converts the Series C, usually anchors at, historical $1.10 → $1.22 → $1.54 → $2.72 , in June 2026 converted 50 to 408k at around $1.224 which I'd say hit in August and I don't think there are many left.
0 · Reply
Maxandbear
Maxandbear Sep. 5 at 9:47 AM
$PPCB this with rocket up and drop down that is why we are trading.
1 · Reply
Maxandbear
Maxandbear Sep. 5 at 9:46 AM
$PPCB i hate drama queens unless the drama queen is a professional stripper
1 · Reply
Funktrade
Funktrade Sep. 4 at 8:03 PM
$PPCB sweet . 2 days and no drop . 🙌🙌🤣🤣
0 · Reply
strong_Dan
strong_Dan Sep. 4 at 4:07 PM
$PPCB Who can check for me how much they let it drown before the May reverse split? :D :)) They can't afford that right now, timely constrained to be delisted, but they still sell, greedy, so, catch the next pump whatever you can since it won't last. I see a close today at 1.30 so they can fake everybody on Tuesday once more.
0 · Reply
URANIUM77
URANIUM77 Sep. 4 at 3:21 PM
$PPCB It is coming
0 · Reply
SHEROCKSMYSTOCKS
SHEROCKSMYSTOCKS Sep. 4 at 1:40 PM
$PPCB keep this on watch get in before the crowds $PLAG $WETO $IMRN $OFAL
0 · Reply
Funktrade
Funktrade Sep. 4 at 11:12 AM
$PPCB had to block DOUCHE_Dan . Trying to analyze me by reading 3 years of comments. I make 5%-10% profit trades all day , every month,and don’t post about it. The troll assumed he knows all. No more Dan now 😆😆😆😆😆😆
0 · Reply
Funktrade
Funktrade Sep. 3 at 9:04 PM
$PPCB feels like a win . Didn’t drop another 10% 🤣🤣🤣
1 · Reply